Stock Traders Purchase Large Volume of Call Options on Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJGet Rating) was the recipient of some unusual options trading on Friday. Stock investors acquired 63,128 call options on the company. This represents an increase of approximately 100% compared to the typical daily volume of 31,559 call options.

Johnson & Johnson Trading Up 1.0 %

Johnson & Johnson stock traded up $1.80 during midday trading on Friday, reaching $176.66. The stock had a trading volume of 303,569 shares, compared to its average volume of 6,717,676. The firm’s fifty day simple moving average is $167.63 and its two-hundred day simple moving average is $171.41. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The firm has a market cap of $461.87 billion, a price-to-earnings ratio of 24.43, a PEG ratio of 3.44 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted $2.60 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson declared that its board has approved a stock buyback program on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.56%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is 62.95%.

Insider Activity at Johnson & Johnson

In related news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 118,795 shares of company stock worth $20,230,174. 0.35% of the stock is owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently bought and sold shares of the stock. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its position in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. IFM Investors Pty Ltd grew its stake in shares of Johnson & Johnson by 20.1% in the first quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock worth $74,259,000 after acquiring an additional 70,221 shares during the last quarter. Essex LLC increased its position in Johnson & Johnson by 3.7% during the first quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after acquiring an additional 1,146 shares during the period. Finally, Callahan Advisors LLC raised its stake in Johnson & Johnson by 1.7% during the 1st quarter. Callahan Advisors LLC now owns 119,240 shares of the company’s stock valued at $21,133,000 after purchasing an additional 1,963 shares during the last quarter. 68.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Barclays began coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Citigroup dropped their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Credit Suisse Group assumed coverage on Johnson & Johnson in a report on Thursday. They set a “neutral” rating and a $170.00 target price for the company. Finally, UBS Group cut their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.